181 related articles for article (PubMed ID: 37352385)
1. Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer.
Pizurica M; Larmuseau M; Van der Eecken K; de Schaetzen van Brienen L; Carrillo-Perez F; Isphording S; Lumen N; Van Dorpe J; Ost P; Verbeke S; Gevaert O; Marchal K
Cancer Res; 2023 Sep; 83(17):2970-2984. PubMed ID: 37352385
[TBL] [Abstract][Full Text] [Related]
2. Using Machine Learning to Predict TP53 Mutation Status and Aggressiveness of Prostate Cancer from Routine Histology Images.
Bordeleau F
Cancer Res; 2023 Sep; 83(17):2809-2810. PubMed ID: 37655432
[TBL] [Abstract][Full Text] [Related]
3. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer.
Chipidza FE; Alshalalfa M; Mahal BA; Karnes RJ; Liu Y; Davicioni E; Martin NE; Mouw KW; Feng FY; Nguyen PL; Muralidhar V
Clin Genitourin Cancer; 2021 Jun; 19(3):246-254.e5. PubMed ID: 32896505
[TBL] [Abstract][Full Text] [Related]
5. Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis?
Roy-Burman P; Zheng J; Miller GJ
Mol Med Today; 1997 Nov; 3(11):476-82. PubMed ID: 9430782
[TBL] [Abstract][Full Text] [Related]
6. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
7. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of
Guedes LB; Almutairi F; Haffner MC; Rajoria G; Liu Z; Klimek S; Zoino R; Yousefi K; Sharma R; De Marzo AM; Netto GJ; Isaacs WB; Ross AE; Schaeffer EM; Lotan TL
Clin Cancer Res; 2017 Aug; 23(16):4693-4703. PubMed ID: 28446506
[No Abstract] [Full Text] [Related]
8. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer.
Xu X; Xie L; Meng L; Geng S; Liu J; Cao X; Dong Z; Xing Z
Biosci Trends; 2022 Jul; 16(3):221-229. PubMed ID: 35768267
[TBL] [Abstract][Full Text] [Related]
9. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
10. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
11. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
[TBL] [Abstract][Full Text] [Related]
12. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
13. Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.
Gesztes W; Schafer C; Young D; Fox J; Jiang J; Chen Y; Kuo HC; Mwamukonda KB; Dobi A; Burke AP; Moul JW; McLeod DG; Rosner IL; Petrovics G; Tan SH; Cullen J; Srivastava S; Sesterhenn IA
Sci Rep; 2022 Mar; 12(1):5404. PubMed ID: 35354846
[TBL] [Abstract][Full Text] [Related]
14. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.
Wertz IE; Deitch AD; Gumerlock PH; Gandour-Edwards R; Chi SG; de Vere White RW
Hum Pathol; 1996 Jun; 27(6):573-80. PubMed ID: 8666367
[TBL] [Abstract][Full Text] [Related]
15. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
[TBL] [Abstract][Full Text] [Related]
16. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.
Vinall RL; Chen JQ; Hubbard NE; Sulaimon SS; Shen MM; Devere White RW; Borowsky AD
Dis Model Mech; 2012 Nov; 5(6):914-20. PubMed ID: 22563073
[TBL] [Abstract][Full Text] [Related]
17. A CD24-p53 axis contributes to African American prostate cancer disparities.
Liu W; Zhang Y; Wei S; Bae S; Yang WH; Smith GJ; Mohler JL; Fontham ETH; Bensen JT; Sonpavde GP; Chen GY; Liu R; Wang L
Prostate; 2020 May; 80(8):609-618. PubMed ID: 32168400
[TBL] [Abstract][Full Text] [Related]
18. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations.
Agell L; Hernández S; de Muga S; Lorente JA; Juanpere N; Esgueva R; Serrano S; Gelabert A; Lloreta J
Mod Pathol; 2008 Dec; 21(12):1470-8. PubMed ID: 19020536
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Improving the genetic signature of prostate cancer, the somatic mutations.
Martinez-Gonzalez LJ; Pascual Geler M; Robles Fernandez I; Cozar JM; Lorente JA; Alvarez Cubero MJ
Urol Oncol; 2018 Jun; 36(6):312.e17-312.e23. PubMed ID: 29650325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]